Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia by Khalafallah, Alhossain & Brain, Terry
Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES
Letter to the Editor 
Dose-modified  lenalidomide  induces  sustained  hematological  response  in 
patients with intermediate to 
Published: May 31, 2010
Received:  April 19, 2010
Accepted:  May 20, 2010
Medit J Hemat Infect Dis 2010, 2(2): e2010012, DOI 10.4084/MJHID.2010.
This article is available from: http://www.mjhid.org/article/view/5801
This is an Open Access article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium, provided
   
Dear Editor,
Treating  intermediate  to  high
Myelodysplastic  syndrome  (MDS)  remains  a 
challenge  despite  the  availability  of  new  agents, 
such  as  lenalidomide,  azacitidine,  and  decitabine. 
Thus,  immunomodulating  agents,  especially 
lenalidomide, represent an exciting and promising 
area  of  development  in  the  treatment  of  MDS. 
Dose-escalation  of  lenalidomide  in  treating  MDS 
and  other  hematologic  malignancies  is  asso
with  apparent  side-effects  due  to  hemopoietic 
suppression.  Therefore,  it  is  worthwhile  to  study 
different dosing regimens of lenalidomide and their 
effect on the hematopoiesis of intermediate to high 
risk MDS patients. 
MDS is a clonal heterogeneous hematopoietic 
stem  cell  disorder  characterized  by  ineffective 
hematopoiesis.
1 Successful treatment of MDS aims 
to  decrease  transfusion  dependency,  improve 
patient  survival  and  quality  of  life,
decreasing the likelihood of transformation to acut
myeloid leukemia (AML).
1
Lenalidomide  is  an  immunomodulating  agent 
from  the  immunomodulatory  compounds  (IMiDs) 
class that is employed in the management of several 
hematological  malignancies. It has been  approved 
for the treatment of multiple myeloma and 
myelodysplasia  (MDS),  particularly  in  those 
patients with the cytogenetic abnormality; deletion 
of the long arm of chromosome 5 (5q-).
Hematologic  and  cytogenetic  responses 
achieved  with  lenalidomide  in  MDS  suggest  that 
lenalidomide controls the abnormal MDS clone in 
low-risk disease with a lack of data in other disease 
stages.
4-6 The lenalidomide dose in these
limited  to  5-10  mg  per  day  due  to  drug
myelosuppression.
7,8 Moreover,  low
lenalidomide  results  in  a  lower  plasma
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Treating  intermediate  to  high-risk 
Myelodysplastic  syndrome  (MDS)  remains  a 
challenge  despite  the  availability  of  new  agents, 
azacitidine,  and  decitabine. 
Thus,  immunomodulating  agents,  especially 
lenalidomide, represent  an exciting and promising 
area  of  development  in  the  treatment  of  MDS. 
escalation  of  lenalidomide  in  treating  MDS 
and  other  hematologic  malignancies  is  associated 
effects  due  to  hemopoietic 
suppression.  Therefore,  it  is  worthwhile  to  study 
of lenalidomide and their 
effect on the hematopoiesis of intermediate to high 
hematopoietic 
stem  cell  disorder  characterized  by  ineffective 
Successful treatment of MDS aims 
to  decrease  transfusion  dependency,  improve 
, as  well  as 
decreasing the likelihood of transformation to acute 
Lenalidomide  is  an  immunomodulating  agent 
from  the  immunomodulatory  compounds  (IMiDs) 
class that is employed in the management of several 
hematological  malignancies. It has  been  approved 
for the treatment of multiple myeloma and low-risk 
myelodysplasia  (MDS),  particularly  in  those 
abnormality; deletion 
).
2-3
Hematologic  and  cytogenetic  responses 
achieved  with  lenalidomide  in  MDS  suggest  that 
e abnormal MDS clone in 
risk disease with a lack of data in other disease 
The lenalidomide dose in these trials was 
10  mg  per  day  due  to  drug-related 
Moreover,  low-dose 
lenalidomide  results  in  a  lower  plasma
concentration  of  the  drug compared  with  higher 
dosing strategies.
7-9 Most of these studies report that 
lenalidomide was administered in a dose of 5
daily  for  21  days  of  a  monthly  cycle  to  avoid 
myelosuppression.  There  is  no  available  data 
regarding  dividing  the  monthly  dose  of 
lenalidomide (total dose: 105-210 mg) evenly into 
two doses of 15 mg per week (total dose: 120 mg 
monthly) in order to improve  patient tolerance
We describe two patients with MDS who were 
commenced on lenalidomide therapy between April 
2009  and  January  2010.  Before  lenalidomide 
treatment,  both  patients  required  regular  blood 
transfusions every 1-4  weeks despite  recombinant 
erythropoietin  treatment. Therefore,  both  patients 
were  commenced  on  lenalidomide  therapy  in 
addition  to  erythropoietin  because  of  progressive 
and symptomatic anemia in conjunction with severe 
pancytopenia.  Both  patients  had  stable  normal 
karyotype prior to commencement of lenalid
therapy.  They  have  maintained  long
transfusion independence (over 10 months in case 1 
and 5 months in case 2) while receiving continuous 
oral  lenalidomide  therapy,  15  mg  twice  weekly. 
Sustained erythroid response with improvement of 
neutrophil and platelet counts to normal
and  subnormal  in  case  1 with  the  twice  weekly 
dose. The modified dose was commenced based on 
the following factors; firstly, both patients suffered 
from severe pancytopenia, therefore the daily dose 
of lenalidomide may have an undesirable effect on 
myelopoiesis  or  megakaryopoiesis.  Secondly,  a 
relatively  higher  dose  of  15  mg  twice  weekly 
lenalidomide  will  theoretically  achieve  a  higher 
plasma concentration of lenalidomide on the days of 
administration, which  may have  a
on the malignant  MDS clone than does the usual 
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compared  with  higher 
Most of these studies report that 
lenalidomide was administered in a dose of 5-10 mg 
daily  for  21  days  of  a  monthly  cycle  to  avoid 
o  available  data 
dividing  the  monthly  dose  of 
210 mg) evenly into 
two doses of 15 mg per week (total dose: 120 mg 
patient tolerance. 
We describe two patients with MDS who were 
commenced on lenalidomide therapy between April 
2009  and  January  2010.  Before  lenalidomide 
treatment,  both  patients  required  regular  blood 
4  weeks  despite  recombinant 
Therefore,  both  patients 
were  commenced  on  lenalidomide  therapy  in 
addition  to  erythropoietin  because  of  progressive 
and symptomatic anemia in conjunction with severe 
pancytopenia.  Both  patients  had  stable  normal 
karyotype prior to commencement of lenalidomide 
therapy.  They  have  maintained  long-term 
transfusion independence (over 10 months in case 1 
and 5 months in case 2) while receiving continuous 
oral  lenalidomide  therapy,  15  mg  twice  weekly. 
Sustained erythroid response with improvement of 
counts to normal in case 2
with  the  twice  weekly 
dose. The modified dose was commenced based on 
the following factors; firstly, both patients suffered 
from severe pancytopenia, therefore the daily dose 
y have an undesirable effect on 
myelopoiesis  or  megakaryopoiesis.  Secondly,  a 
relatively  higher  dose  of  15  mg  twice  weekly 
lenalidomide  will  theoretically  achieve  a  higher 
plasma concentration of lenalidomide on the days of 
which may have  a different  effect 
on the malignant  MDS clone than does the usual Medit J Hemat Infect Dis 2010; 2(2); Open Journal System 
daily dose of 5 mg.
7,9 Lastly, the dosing regimen of 
lenalidomide  in  multiple  myeloma  disease 
incorporates  a  higher  daily  dose,  between  15  mg 
and 25 mg, for a 21 day cycle every 28 days.  Both 
patients consented to this treatment having refused 
other chemotherapeutic options. The patients were 
treated  under  the  special  access  scheme  of  the 
Therapeutic Goods Administration, Department of 
Health and Aging, Australian Government. 
The  first  patient,  a  75-year-old  Caucasian 
female was diagnosed with MDS 4 years prior to 
the lenalidomide therapy. The initial bone marrow 
biopsy showed up to 5-10 % myeloblasts expressing 
CD13, 33, 34 and 117 in keeping with intermediate-
1 risk MDS, based on the International Prognostic 
Scoring  System  (IPSS)
10 with  no  abnormal 
cytogenetics detected.  After 2 ½ years she became 
transfusion-dependent at a frequency of 2-4 weeks 
despite erythropoietin treatment. Since commencing 
lenalidomide, 15 mg twice weekly, she  developed a 
sustained  erythroid  response  without  the  need  for 
blood transfusion for 10 months thereafter.
The  second  patient,  a  73-year-old  Caucasian 
male  with  MDS  was  diagnosed  31  months  pre-
lenalidomide  therapy.  A  bone  marrow  biopsy 
performed  in  March  2007  showed  tri-lineage 
dysplasia  and  5-10%  myeloblasts  consistent  with 
intermediate-1  risk  MDS  according  to  IPSS.  
Myeloblasts  were  expressing  CD34,  33,  117  and 
CD 13 in keeping with MDS. Cytogenetic analysis 
showed  normal  male  karyotype.  A  repeat  of  the 
bone  marrow  biopsy  2  years  later  revealed  an 
increase of the myeloblasts, up to 20%, expressing 
the same phenotype. At the time of commencement 
of  lenalidomide,    IPSS  score  was  consistent  with 
intermediate  to  high-risk  MDS.  He  developed 
severe  pancytopenia  12  months  pre-lenalidomide 
therapy and became transfusion dependent with the 
requirement for blood transfusions every 1-2 weeks. 
Therefore,  treatment  with  lenalidomide was 
initiated  in  August  2009.  Unexpectedly,  the 
pancytopenia  recovered  completely  a  few  weeks 
after  commencement  of  lenalidomide,  thus 
eliminating his transfusion requirements thereafter
with  cessation  of  erythropietin.    Although  the 
hemoglobin (Hb) levels were maintained above 10 
g/dl,  the  platelets  and  neutrophil  counts  dropped 
after 5  months of  treatment  but stayed  above the 
initial levels. 
There are several MDS trials employing a daily 
dose of lenalidomide between 5-10 mg with varying 
degrees of patient tolerability.
4-8 However, there is 
no data available regarding dividing the total dose 
of  35 mg  of  lenalidomide  per  week  into  two  or 
more doses of 15 mg weekly in order to achieve a 
higher  concentration  of  lenalidomide  in  plasma 
during the days of administration and hence achieve 
a desirable effect on the malignant MDS clone.
Although the precise mechanism of action of 
lenalidomide  remains  unknown,  it  does  exhibit 
antineoplastic and immunomodulatory properties.
2,3
In  patients  with  low-risk  MDS,  lenalidomide 
reduces  the  need  for  blood  transfusions  and  is 
essential  for  sustained  restoration  of  effective 
erythropoiesis.
6,7 Lenalidomide  affects  the  signal 
transduction  pathway  that  possibly  explains  its 
selective effect on subsets of MDS and may explain 
the improvement of the other blood counts in the 
second case. While the exact molecular targets of 
lenalidomide remain unknown, its activity across a 
spectrum  of  neoplastic  conditions  highlights  the 
possibility of multiple target sites of action.
2,3
In a phase 2 trial  for  CLL, lenalidomide was 
administered at 10 mg daily with a dose-escalation 
of 5 mg every 28 days, however due to significant 
hematologic  toxicity,  the  average  delivered  dose 
was 10 mg in this cohort of patients.
9 This study 
suggested  that  continuous low-dose  lenalidomide 
may be as effective as an interrupted regimen using 
a  higher  dose.
9 However,  the  previous study 
demonstrated  that  the  10 mg  daily  dose  showed 
significant  hematologic  toxicity  with  30%  of 
patients  developed tumor-flare  reactions  that  may 
have been attributed to the continuous daily dose of 
lenalidomide. 
In  our  series,  immunomodulation  with 
lenalidomide at a dose of 15 mg twice weekly has 
achieved  a  durable  hematological  response  in 
intermediate  to high-risk  MDS  patients. 
Furthermore,  lenalidomide  has  altered the  disease 
course  for  these  patients  and  has  improved  their 
quality  of  life  without  blood  transfusion 
dependency. The drug in its modified dose has been 
well tolerated without side effects.
The  favorable  outcomes  presented  here  show 
that  twice  weekly  lenalidomide dose induced  not 
only  erythroid  responses  but  also  enhanced 
myelopoiesis and megakaryopoiesis as seen in case 
2. However, the exact mechanism of the effect of 
lenalidonide in different doses on myelopoiesis and 
mega-karyopoiesis  of  MDS  patients  should  be 
further studied. Medit J Hemat Infect Dis 2010; 2(2): Open Journal System
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